{"id":2154,"date":"2007-12-01T12:06:00","date_gmt":"2007-12-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/ruhen-der-zulassung-von-lumiracoxib-prexige"},"modified":"2007-12-01T12:06:00","modified_gmt":"2007-12-01T11:06:00","slug":"ruhen-der-zulassung-von-lumiracoxib-prexige","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/ruhen-der-zulassung-von-lumiracoxib-prexige","title":{"rendered":"Ruhen der Zulassung von Lumiracoxib (Prexige\u00ae)"},"content":{"rendered":"<p>Das Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) hat am 9. November 2007 das Ruhen der Zulassung f\u00fcr Lumiracoxib (L) bekannt gegeben (1, 2). Erst seit Januar 2007 war es in Deutschland zur Behandlung von Arthroseschmerzen verf\u00fcgbar. Im August waren in Australien schwere toxische Lebersch\u00e4den bei Patienten aufgefallen, die mit 400 mg L behandelt worden waren. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) hat am 9. November 2007 das Ruhen der Zulassung f\u00fcr Lumiracoxib (L) bekannt gegeben (1, 2). Erst seit Januar 2007 war es in Deutschland zur Behandlung von Arthroseschmerzen verf\u00fcgbar. Im August waren in Australien schwere toxische Lebersch\u00e4den bei Patienten aufgefallen, die mit 400 mg L behandelt worden waren. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1355,1360,2982,2983,1350],"class_list":["post-2154","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-cox-2-hemmer","tag-coxibe","tag-lumiracoxib","tag-prexige","tag-zyklooxygenase-2-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2154"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2154\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}